WINREVAIR met the primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality. This data is from the interim analysis of the Phase 3 ZENITH trial. The study has been stopped early and participants will be offered the opportunity to receive WINREVAIR.
WINREVAIR is currently approved for pulmonary arterial hypertension patients in functional class II and III (see Food and Drug Administration (FDA) approval at this link and European Medicines Agency (EMA) approval here.
Read more on MERCK press release at this link
Photo credit: https://www.winrevair.com/
